Ligand-based molecular design of 4-benzylpiperidinealkylureas and amides as CCR3 antagonists

Journal of Molecular Modeling

Volumn 16, Issue 4, 2010, Pages 669-676

  Jain, Vaibhav ^a   Pandey, Ashish ^a   Gupta, Shikhar ^a   Mohan, C Gopi ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

3D QSAR; Asthma; CCR3 antagonist; CoMFA

Indexed keywords

4 BENZYLPIPERIDINEALKYLUREA; AMIDE; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CCR3; LIGAND; PIPERIDINE DERIVATIVE; UNCLASSIFIED DRUG; BENZENE DERIVATIVE; CCR3 PROTEIN, HUMAN; UREA;

ARTICLE; ASTHMA; CHEMICAL STRUCTURE; COMPARATIVE MOLECULAR FIELD ANALYSIS; MOLECULAR MODEL; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PROPHYLAXIS; QUANTITATIVE STRUCTURE ACTIVITY RELATION; STRUCTURE ACTIVITY RELATION; THREE DIMENSIONAL IMAGING; CHEMISTRY; DRUG ANTAGONISM; DRUG DESIGN; HUMAN; PATHOLOGY;

AMIDES; ASTHMA; BENZENE DERIVATIVES; DRUG DESIGN; HUMANS; LIGANDS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RECEPTORS, CCR3; UREA;

EID: 77954602752     PISSN: 16102940     EISSN: 09485023     Source Type: Journal    
DOI: 10.1007/s00894-009-0621-z     Document Type: Article

References (25)

1. Gleich GJ, Adolphson CR (2000) The eosinophil and asthma. In: busse WW, Holgate ST (eds) Asthma and rhinitis, 2nd edn. Blackwell, Oxford, pp 419-470.
2. Gleich GJ (1990) The eosinophil and bronchial asthma: current understanding. J Allergy Clin Immunol 85:422-436.
3. Griffiths-Johnson DA, Collins PD, Rossi AG, Jose PJ, Williams TJ (1993) The chemokine, eotaxin, activates guinea-pig eosinophils in vitro and causes their accumulation into the lung in vivo. Biochem Biophys Res Commun 197:1167-1172.
4. Kampen GT, Stafford S, Adachi T, Jinquan T, Quan S, Grant JA, Skov PS, Poulsen LK, Alam R (2000) Eotaxin induces degranulation and chemotaxis of eosinophils through the activation of ERK2 and p38 mitogen-activated protein kinases. Blood 95:1911-1917.
5. Murphy PM, Baggiolini M, Charo IF, Hebert CA, Horuk R, Matsushima K, Miller LH, Oppenheim JJ, Power CA (2000) International union of pharmacology. XXII nomenclature for chemokine receptors. Pharmacol Rev 52:145-176.
6. Zlotnik A, Yoshie O (2000) Chemokines: a new classification system and their role in immunity. Immunity 12:121-127.
7. Bertrand CP, Donath PD (2000) CCR3 blockade as a new therapy for asthma. Expert Opin Invest Drugs 9:43-52.
8. Duchesnes CE, Murphy PM, Williams TJ, Pease JE (2006) Alanine scanning mutagenesis of the chemokine receptor CCR3 reveals distinct extracellular residues involved in recognition of the eotaxin family of chemokines. Mol Immunol 43:1221-1231.
9. Wise EL, Duchesnes C, da Fonseca PCA, Allen RA, Williams TJ, Pease JE (2007) Small compound receptor agonists and antagonists of CCR3 provide insight into mechanisms of chemokine receptor activation. J Biol Chem 282:27935-27943.
10. Berger EA, Murphy PM, Farber JM (1999) Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol 17:657-700.
11. Alkhatib G, Berger EA, Murphy PM, Pease JE (1997) Determinants of HIV-1 coreceptor function on CC chemokine receptor 3, importance of both extracellular and transmembrane/cytoplasmic regions. J Biol Chem 272:20420-20426.
12. Boehme SA, Sullivan SK, Crowe PD, Santos M, Conlon PJ, Sriramarao P, Bacon KB (1999) Activation of mitogen-activated protein kinase regulates eotaxin-induced eosinophil migration. J Immunol 163:1611-1618.
13. El-Shazly A (2003) Basic concepts in eosinophil recruitment to sites of allergic inflammation: an in vitro model of the pathophysiology of late response in allergic rhinitis. Int Congr Ser 1240:1081-1086.
14. Pease JE, Wang J, Ponath PD, Murphy PM (1998) The N-terminal extracellular segments of the chemokine receptors CCR1 and CCR3 are determinants for MIP-1alpha and eotaxin binding, respectively, but a second domain is essential for efficient receptor activation. J Biol Chem 273:19972-19976.
15. Vedani A, Dobler M, Dollinger H, Hasselbach KM, Birke F, Lill MA (2005) Novel ligands for the chemokinereceptor-3 (CCR3):a receptor-modeling study based on 5D-QSAR. J Med Chem 48:1515-1527.
16. Kubinyi H (2006) Special Publication. Royal Society of Chemistry 304:219-240.
17. Awale M, Mohan CG (2008) Molecular docking guided 3D-QSAR CoMFA analysis of N-4-pyrimidinyl-1H-indazol-4-amine inhibitors of leukocyte-specific protein tyrosine kinase. J Mol Model 14:937-947.
18. Awale M, Mohan CG (2008) 3D QSAR CoMFA analysis of C5 substituted pyrrolotriazines as HER2 (ErbB2) inhibitors. J Mol Graph Model 26:1169-1178.
19. Garg D, Gandhi T, Mohan CG (2008) Exploring QSTR and toxicophore of hERG K+ channel blockers using GFA and HypoGen techniques. J Mol Graph Model 26:966-976.
20. Wold S, Johansson A, Cochi M (1993) In: Kubinyi H (ed) 3D QSAR in drug design: theory, methods and applications. ESCOM, Lieden, pp 523-550.
21. Wacker DA, Santella IJ, Gardner DS, Varnes JG, Estrella M, DeLucca GV, Ko SS, Tanabe K, Watson PS, Welch PK (2002) CCR3 antagonists: a potential new therapy for the treatment of asthma. Discovery and structure-activity relationships. Bioorg Med Chem Lett 12:1785-1789.
22. Cramer RD III, Patterson DE, Bunce JD (1988) Effect of shape on binding of steroids to carrier proteins. J Am Chem Soc 110:5959- 5967.
23. SYBYL7.1, Tripos Inc, St Louis, MO.
24. Clark M, Cramer RD, Van Opdenbosch N (1989) Validation of the general purpose tripos 5.2 force field. J Comput Chem 10:982-1012.
25. Cramer RD, Bunce JD, Patterson DE, Frank IE (1988) Cross validation, bootstrapping and partial least squares compared with multiple regression in conventional QSAR studies. Quant Struct Act Relat 7:18-25.